Judge Nixes Dismissal Bid In Thalomid Antitrust Suit

Law360, New York (March 31, 2011, 4:21 PM EDT) -- A federal judge in Pennsylvania on Thursday denied a second attempt by Celgene Corp. to dismiss an antitrust complaint by a generics maker that wants to market a version of the company's thalidomide-based cancer drug Thalomid.

The one-sentence order marks the second time Judge Timothy J. Savage of the U.S. District Court for the Eastern District of Pennsylvania has tossed a Celgene motion to dismiss Lannet Co.'s suit.

In its complaint filed in 2008, generic-drug maker Lannett accused Celgene of violating the Sherman Antitrust Act by...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.